Global Health Institute
Global Health Institute (GHI) is new international partnership between CITIID/University of Cambridge, the University of Hong Kong (HKU), and the International Vaccine Institute (IVI) in Seoul. Established in March 2024, with the generous support of the Hong Kong Jockey Club Charities Trust, the institute aims to enhance global preparedness for future pandemics by advancing vaccine research, development, and implementation.
The GHI will benefit from IVI’s expertise in vaccine development, HKU’s leadership in pandemic virology and epidemiology, and CITIIDs strength in human immunology. Together, it will unite world-leading scientists and research teams to foster collaboration and innovation in vaccine research.
Cambridge-GSK Translational Immunology Collaboration (CG-TIC)
CG-TIC is an exciting collaboration that combines University of Cambridge and GSK expertise in human immunology and immune-mediated diseases, AI and clinical development, with access to patient data and samples provided by Cambridge University Hospitals. GSK has made a £53M investment over 5 years to better understand kidney and respiratory diseases.
The kidney disease projects are led by CITIID Group Leaders, with GSK collaborators, building large datasets that include clinical data, information on genetic variation, deep phenotyping of blood and tissue cells, and a variety of in vitro models to better understand factors underpinning disease onset and progression, how patients respond to therapies and on developing biomarkers for rapid diagnosis. Ultimately, the goal is to trial more effective, personalised medicines.
